CORRECTING and REPLACING Veeva Vault PromoMats selected by Roche for Digital Asset Management and Content
4.12.2018 15:53:00 EET | Business Wire | Press release
The fifth paragraph has been removed from the release.
The corrected release reads:
VEEVA VAULT PROMOMATS SELECTED BY ROCHE FOR DIGITAL ASSET MANAGEMENT AND CONTENT
Vault PromoMats combines digital asset management with medical, legal, regulatory review to streamline content management and distribution
2018 Veeva European Commercial & Medical Summit - Veeva Systems (NYSE:VEEV) today announced that Roche (SWX:ROG) is adopting Veeva Vault PromoMats as their global content and digital asset management (DAM) solution.
“We are proud to partner with Roche on this important initiative to speed time to market of their commercial and medical content,” said John Chinnici, vice president of commercial content at Veeva. “Vault PromoMats gives the life sciences industry a single solution to easily create and distribute content with integrated capabilities to manage rich digital assets.”
Vault PromoMats is the first and only application that combines digital asset management with medical, legal, and regulatory review. Companies can eliminate the need to move, duplicate, and manage content and digital assets across multiple systems for improved visibility, control, and compliance throughout the digital supply chain.
In other news, Veeva introduced Veeva Vault Digital Publishing, a new digital asset management capability in Vault PromoMats and Vault MedComms for brand marketing teams to publish and withdraw approved assets from a central location to any digital channel for faster and easier publishing. Read today’s press release to learn more.
Additional Information
For more on Veeva Vault PromoMats, visit: veeva.com/eu/PromoMats
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_EU
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 675 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2018. This is available on the company’s website at veeva.com/eu under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
###
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181204005399/en/
Contact information
Roger Villareal
Veeva Systems
+1-
925-264-8885
roger.villareal@veeva.com
Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio ® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis30.9.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, is presenting new three-year data from the ARCADIA long-term extension study, demonstrating that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis.1 The findings will be shared in an oral presentation, titled ‘Long-term safety and efficacy (up to 152 weeks) of nemolizumab in ARCADIA open-label extension study in adults and adolescents with moderate-to-severe atopic dermatitis’, at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, on Thursday, October 1, from 10:45-10:55 AM CET in Hall N by Dr. Matthias Augustin, an ARCADIA clinical trial investigator. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929663019/en/ “These three-year data provide important evi
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill30.9.2026 08:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from threePhase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis.1 Presented during late-breaking and oral sessions at the European Academy of Dermatology & Venereology (EADV) Congress 2026, these results demonstrate zasocitinib’s superior efficacy compared to deucravacitinib and reinforce the potential for zasocitinib to deliver rapid, durable and consistent skin clearance in a convenient once-daily pill.2-5 “Psoriasis is a heterogeneous disease driven by multiple immune pathways and TYK2 plays a central role in regulating several key inflammatory signals,” said Chinwe Ukomadu, M.D., Ph.D., Senior Vice President and Head, Gastrointestinal & Inflammation Therapeutic Area Unit at Takeda. “Across our Phase 3 trials, zasocitinib demonstrated superiority versus two distinct oral thera
Ant International’s Antom Supports Google Gemini in Expanding Access to AI Service in Asia30.9.2026 07:16:00 EEST | Press release
Google Gemini and Antom, a leading merchant payment and digitisation services provider under Ant International, today announced a strategic partnership to make AI tools for learning, creativity and productivity more accessible to users in Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929520038/en/ Google AI Plus free trial offers are available in select digital payment and retail channels partnering with A+Rewards in Indonesia, with more markets to follow. Promoting Google AI Plus through AI-powered growth engine The collaboration will leverage A+Rewards, Antom’s digital marketing solution powered by privacy-preserving computing and AI technologies, and its extensive partner network of digital payment apps, e-commerce platforms and lifestyle service providers, to help expand access to Google AI Plus. Integrated into more than 30 leading digital platform partners, A+ Rewards provides in-app entry points where users
Signaloid Joins CERN openlab's Heterogeneous Architectures Testbed to Explore the Future of Scientific Computing30.9.2026 07:00:00 EEST | Press release
British computing company Signaloid has joined CERN openlab, the public-private partnership through which CERN evaluates emerging information technologies for scientific computing. As part of the collaboration, CERN and Signaloid will evaluate Signaloid's distribution-extended compute hardware (UxHw®) technology within the CERN openlab Heterogeneous Architectures Testbed, which explores new processor technologies for future scientific computing infrastructures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929985154/en/ Signaloid joins CERN openlab: Putting Signaloid's UxHw® Technology to the Test at the World's Largest Particle Collider The collaboration comes as research organisations worldwide are increasingly adopting heterogeneous computing architectures that combine CPUs, GPUs and specialised accelerators to tackle demanding workloads more efficiently. As the High-Luminosity Large Hadron Collider (HiLumi LHC) appro
FPT Named in Forrester’s The SAP Services Landscape Report30.9.2026 06:00:00 EEST | Press release
Global technology corporation FPT has been included among the notable providers in The SAP Services Landscape, Q3 2026, published by Forrester Research, Inc. The report provides an overview of SAP services providers, examining their market focus, geographic presence, and business specializations to support enterprises in evaluating potential technology partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929359531/en/ The report includes FPT as a systems integrator with an Asia Pacific geographic focus and an industry focus spanning financial services and insurance, healthcare, and manufacturing. FPT identified SAP Business Data Cloud, SAP Enterprise Resource Planning (ERP), and SAP Supply Chain Management (SCM) as its three primary extended business scenario focus areas, what FPT believes reflects its emphasis on modernizing core enterprise systems and enabling more integrated, data-driven operations. Building on mor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom